Daptoced

INDICATIONS	DOSAGE
Adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (CSSSI) caused by susceptible isolates of the following Gram- positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only)	4 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 7 to 14 days.
Adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin- resistant isolates.	6 mg/kg should be administered intravenously in 0.9% sodium chloride injection once every 24 hours for 2 to 6 weeks.

Daptomycin should be administered intravenously either by injection over a 2 minute period or by infusion over a 30 minute period.

Daptomycin exhibits linear pharmacokinetics at doses up to 12 mg/kg/day and has been shown to be safe and efficacious for the treatment of complicated skin and skin structure infections (cSSSI), bacteremia, and right-sided infective endocarditis caused by susceptible Gram-positive bacteria in adults.
According to post-marketing studies, Daptomycin is a valuable treatment option in the management of other Gram-positive and difficult-to-treat infections, including left-sided endocarditis, osteomyelitis, prosthetic infections, and enterococcal infections.
On the basis of its pharmacokinetic profile and dose-dependent bactericidal activity, higher doses of Daptomycin may be beneficial in treating severe infections. High-dose (>6 mg/kg/day) Daptomycin used in the post-marketing observational studies exhibited a good safety and tolerability profile.
Daptomycin given in combination with other antibiotics may lead to resolution of
various complex and resistant Gram-positive infections and may have a role (along
with high-dose therapy) in minimizing the development of resistance.
Daptomycin appears promising as a safe and efficacious drug for the treatment of pediatric diseases caused by Gram-positive pathogens.
Daptomycin is recognized as an important agent in outpatient parenteral antimicrobial therapy practice due to its spectrum of activity and ease of administration.

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents

Common primary infections	No. of patients-81 (included children and adolescent)
Bacteremia	19.8%
Complicated skin and soft-tissue infection	18.5%
Osteomyelitis	13.6%
Endocarditis	12.3%
Prosthetic infection	12.3%
Uncomplicated skin and soft-tissue infection	9.9%
Other infections	13.6%